Allison Betof, MD, PhD, FASCO· @DrBetofMDPhD · X·· 2 天前评分70
正文 · 机器翻译
在 INMC 会议上，与最优秀的同事和朋友共同开启 #ESMO26。@Liz_htx03 发挥了出色的领导力。这是一个激动人心的时代——我们已经确定新辅助 IO 优于辅助 IO。下一步该何去何从？确定 <pCR 的风险阈值、生物标志物、新联合方案等。
798 浏览 · 17 赞 · 5 转发 · 1 回复
会议摘要
Impact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial
https://esmocongress.esmo.org帖内回复
- Ed Williams@EdWilli63968626
@DrBetofMDPhD @Liz_htx03 Some one better send the news to Merck/Moderna!!!! Some how I think they believe in new personal vaccine that they have some data on that might force a comparison going forward of these two schools of thought!!! I do like neo-adjuvant NADINA model and having melanoma present!
来源：Allison Betof, MD, PhD, FASCO · x.com